Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-25
KRON [neutral]
Kronos Bio, Inc.
-0.24%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States.
Market Cap
$45.1M
Pitch Price
$0.88
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.98
P/E
-0.69
EV/Sales
-3.32
Sector
Biotechnology
Category
special_situation
KRON: Insider-Aligned Biopharma Faces Challenges and Opportunities
KRON (strategic review): Trading 30% below est. Q1'25 net cash post-drug failure. Strategic review ongoing, pre-clinical pipeline may be licensed. 25% insider ownership (CEO stake meaningful). No layoffs announced yet. Staggered board, no major outside shareholders. Intriguing but uncertain situation.
Read full article (1 min)